AVR 4.08% $12.49 anteris technologies ltd

I've spoken to JChick about this now. He's re-iterated that the...

  1. 1,142 Posts.
    lightbulb Created with Sketch. 1
    I've spoken to JChick about this now. He's re-iterated that the Immunotherapies arm has "sufficient capital" for the Head and Neck study and ongoing activities but will seek other options regarding funding. He "doesn't see" the vax arm being funded from the Admedus balance sheet in the future.

    Also covered: Divestment still possible, but would have to come with investment into the immunotherapies business. Where that investment would come from is currently a mystery.
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.